Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Dr. Tyurin Michael
A pharmaceutical company is developing a new drug candidate for the treatment of a chronic disease. One of the critical steps in drug development understands how the drug is metabolized in the body, which can impact its efficacy and safety.
The company needs to analyze the metabolic pathways and identify metabolites produced when the drug is administered to living organisms.
They employ liquid chromatography-mass spectrometry (LC-MS), a powerful technique that combines separation capabilities of chromatography with the mass analysis capabilities of mass spectrometry. LC-MS allows them to separate and quantify different metabolites formed during drug metabolism.
By using LC-MS, the company identifies multiple metabolites produced in various organs, helping them understand the drug’s fate in the body. This knowledge guides further optimization of the drug’s structure and dosage, ensuring its effectiveness and safety.